University of Calgary gastrointestinal surgeon and diabetes researcher Dr. Oliver Frank Bathe has joined M Pharmaceutical’s (CSE:MQ) (OTCQB:MPHMF) Advisory Board.
Dr. Bathe, MD, MSc, FRCS(C), FACS, who currently serves as a full professor at the Division of Surgical Oncology at the Tom Baker Cancer Centre and is a member of the Julia McFarlane Diabetes Center at the University of Calgary, brings to M Pharmaceutical, Inc. his experience in the fields of metabolomics, cancer surgery, epidemiology, and critical care.
Dr. Bathe has also served as the provincial leader of the Gastrointestinal Tumour Team at the Tom Baker Centre for the past two years and he is widely-published in his core fields of diabetes mellitus, surgery and oncology.
"The wealth and scope of knowledge associated with Dr. Bathe, especially in areas of diabetes, gastrointestinal and hepatobiliary surgery, and critical care, will only strengthen our company's capacity in the pursuit of excellence with respect to our innovative biomedical technologies," said M Pharmaceutical’s president and CEO, Dr. Martin Mintchev.
Dr. Bathe’s expertise in gastrointestinal surgery, and diabetes mellitus, makes him “a natural fit for our company as we move toward the final development and launch of M Pharmaceutical biomedical technologies such as the e-Mosquito, gastro-intestinal neurostimulators and pseudobezoars,” added Dr. Mintchev.
Dr. Bathe has gathered international experience in diabetes research, surgery and oncology having been a resident and clinical fellow at the St. Paul's Hospital in Vancouver, the University of Miami's Sylvester Comprehensive Cancer Care Centre and University of British Columbia. His students, moreover, have gone on to win more than 30 individual awards and scholarships in Canada and throughout North America.
"We welcome Dr. Bathe to an M Pharmaceutical, Inc. Advisory Board that also includes research and technology leaders such as Douglas Janzen, Dr. Orly Yadid-Pecht and Dr. Michel Fattouche. Their guidance and leadership will add value to our strategic plan around product development and commitment to providing positive solutions for those living with obesity and diabetes," noted Dr. Mintchev.
M Pharma is pursuing an ambitious brand development strategy as it builds on a successful round of biotech acquisitions focused on the treatment of diabetes and obesity.
Over the past year, M Pharmaceutical Inc. has acquired three biomedical technologies addressing obesity and diabetes in a less invasive manner than its market competitors.